Enveric Biosciences Inc vs Toast Inc. Class A Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Toast Inc. Class A Common Stock trades at $29.65 (market cap $17.85B). The key difference: Toast Inc. Class A Common Stock is far larger — about 2846.9× Enveric Biosciences Inc's market cap, and Toast Inc. Class A Common Stock is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| ENVB | TOST | |
|---|---|---|
Market Cap | $6.27M | $17.85B |
Volume | 100,675 | 6,311,718 |
Sector | Health | Technology |
52-Week High | $10.80 | $39.02 |
52-Week Low | $1.27 | $22.33 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $16.10B |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →